Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb

This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule

Merck Life Science in India has signed a Memorandum of Understanding (MoU) with Aragen, a leading R&D and manufacturing solutions provider, in small molecules and biologics, to the global life sciences industries, a leader in drug discovery in Bangalore.

The MoU was signed by Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science, and Subodh Deshmukh, CEO Aragen Bioscience. The collaboration between Aragen and Merck will facilitate the supply of equipment and technologies for mAb (monoclonal antibody) manufacturing and process development for novel modalities.

This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule and scale up with our support.

The agreement underscores Merck’s extensive commitment to novel modalities and early engagement in R&D with emerging biotechnology startups in the country.